Clinical Trial Update: CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating CAR BCMA-70 CAR-T cells for high-risk plasma cell neoplasms is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CAR BCMA-70 CAR-T Cells

Snippet

Sponsor: Affiliated Hospital to Academy of Military Medical Sciences | Conditions: High-risk Plasma Cell Neoplasms | EARLY_Phase 1 | Status: NOT_YET_RECRUITING